A New Model For A New Era Of Psychedelic Therapy
MAPS Public Benefit Corporation hopes to kick off the next golden age of psychedelic therapy with the potential FDA approval of its MDMA candidate...
Source: lifescienceleader.com
📰 Ben Comer News
Page 4 - Ben Comer News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ben Comer. Real-time updates on events, politics, business and more.
Are Cannabinoids The Next Blockbuster Drugs A QA With Jazz Pharma's CEO Bruce Cozadd
A Q&A with Bruce Cozadd, chairman and CEO of Jazz Pharmaceuticals, on the $7.2 billion acquisition, integration, and future of cannabis drug...
Source: lifescienceleader.com
MAPS Walking The Talk On Intellectual Property
Did MAPS, a leader in the psychedelic medicines space, just make good on its promise to share its intellectual property, as opposed to wielding it...
Source: lifescienceleader.com
Thinking Differently About Rare Disease Therapies
As Ultragenyx continues building its new gene therapy manufacturing facility, CEO and president Dr. Emil Kakkis talks about his unique outlook on the...
Emil Kakkis Everylife Foundation For Rare Diseases Ben Comer Chief Editor Life Science Everylife Foundation
Source: lifescienceleader.com
Where Patients Meet Policy The EveryLife Foundation For Rare Diseases
The year before he founded Ultragenyx, Emil Kakkas created the EveryLife Foundation for Rare Diseases, a nonprofit patient advocacy organization...
United States North Carolina Jannie Kennedy Emil Kakkas Regeneron Pharmaceuticals Everylife Foundation For Rare Diseases
Source: lifescienceleader.com
A QA With A Venture CapitalistGenetic Medicines Executive
Small biotech companies can improve their fundraising prowess, despite choppy market conditions, by avoiding a few common mistakes. Telling a good...
Source: lifescienceleader.com